Invest in ME Conference 12: First Class in Every Way
OverTheHills wraps up our series of articles on this year's 12th Invest in ME International Conference (IIMEC12) in London with some reflections on her experience as a patient attending the conference for the first time.
Discuss the article on the Forums.

Haukeland Rituximab follow-up study, 21 July 2013: "even higher rates of effect"

Discussion in 'Latest ME/CFS Research' started by Sasha, Jul 22, 2013.

  1. Firestormm


    Cornwall England
    I agree. I am not happy at the thought that a drug like this might be 'thrown' at anyone and everyone with this diagnosis - especially this diagnosis - on a 'sink or swim' basis. I am sure it won't be but very little has yet to be forthcoming from the original authors about why they think those that responded did so. It is a critical nut to crack. If ME is to be established firmly as an autoimmune condition then it must be better explained. Hopefully, this is what will come out of the next publication. Hopefully it won't simply be a repeat of the first. Although a repeat would be nice but you see what I mean :)
  2. MeSci

    MeSci ME/CFS since 1995; activity level 6?

    Cornwall, UK
    I've seen studies where they use the same people as both control and treatment groups, by first following their progress without treatment, and then with, and sometimes again without. Obviously with an illness with so much natural variability as ours, this would be relatively difficult, at least without using objective measurements to determine and match the stage of the illness with and without treatment.
  3. Kate_UK

    Kate_UK Senior Member

    Roy S and Bob like this.

See more popular forum discussions.

Share This Page